Tag: ARDS
COVID-19 ARDS has higher EVLWi and PVPI values than non-COVID-19 ARDS
Compared to acute respiratory distress syndrome (ARDS) patients without COVID-19, patients with COVID-19 had similar lung mechanics, but higher extravascular lung water index (EVLWi) and pulmonary vascular permeability index... read more
Steer Clear of Magnesium for COPD
Knowingly or not, we in emergency medicine tend to lean into the Dutch hypothesis, a 1960s postulate that asthma and COPD are part of a spectrum of common disease (chronic obstructive lung disease), and should be considered... read more
Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS
Current literature addressing the pharmacological principles guiding glucocorticoid (GC) administration in ARDS is scant. This paucity of information may have led to the heterogeneity of treatment protocols and misinterpretation... read more
Precision Medicine in ARDS
Acute respiratory distress syndrome (ARDS) is a devastating critical illness that can be triggered by a wide range of insults and remains associated with a high mortality of around 40%. The search for targeted treatment for... read more
Early Outcomes After Lung Transplantation for Severe COVID-19
The findings from our report show that lung transplantation is the only option for survival in some patients with severe, unresolving COVID-19-associated ARDS, and that the procedure can be done successfully, with good early... read more
Bodily Pain in Survivors of ARDS
Nearly half of acute respiratory distress syndrome (ARDS) survivors reported bodily pain at 6- and 12-month follow-up; one-third reported pain at both time points. Pre-ARDS unemployment, smoking history, and in-ICU opioid... read more
New Therapy Could Protect Lung Function in COVID-19 Patients
There is an urgent need for new drugs for ARDS patients, including those with COVID-19. ARDS in influenza-infected mice is associated with reduced levels of liponucleotides (essential precursors for de novo phospholipid synthesis)... read more
Trend and Pattern of 100 ARDS Patients Teferred for VV ECMO Treatment
Referral to specialized center for venovenous (VV) ECMO treatment should be considered expeditiously in case of refractory ARDS, which is often lethal. Transport of unstable patients, although challenging, is feasible and... read more
Ultrasound Grayscale Analysis in ARDS COVID-19
Recent evidence regarding the novel coronavirus disease 2019 (COVID19) is growing in describing the characteristics of this disease, with main focus on lung morphology. Few data are available regarding the peripheral and... read more
Promoting Evidence-Based Practice in ARDS
There is a dearth of literature addressing interventions to improve implementation of evidence-based practices in acute respiratory distress syndrome (ARDS). Existing interventions to improve clinician knowledge and facilitate... read more
Remestemcel-L reduces ARDS mortality in those under 65 years old
New data shows patients with COVID-19-related Acute Respiratory Distress Syndrome (ARDS) were up to 75 percent less likely to die when treated with remestemcel-L and dexamethasone. The data shows remestemcel-L reduced... read more
Prone Positioning in Spontaneously Breathing Subjects With Moderate or Severe ARDS During Invasive Ventilation
In a retrospective analysis of consecutive intubated subjects with moderate or severe ARDS, related or not to COVID-19, spontaneous breathing during prone positioning (PP) was well tolerated and achieved significant improvement... read more
Decreased Mortality in ARDS Patients Treated with Corticosteroids
The use of glucocorticoids might result in reduced mortality in patients with ARDS. Glucocorticoids might be recommended as an adjunct to standard care for ARDS; however, the optimal dose and duration of steroid therapy remains... read more
Expiratory Flow Limitation During Mechanical Ventilation
Expiratory flow limitation (EFL) is present when the flow cannot rise despite an increase in the expiratory driving pressure. The mechanisms of EFL are debated but are believed to be related to the collapsibility of small... read more
Cardiac Markers Implication in Risk-stratification and Management for COVID-19 Patients
COVID-19 patients with pre-existing coronary artery disease represented a higher abnormal percentage of cardiac markers, accompanied by high mortality and ICU admission rate. BNP together with hs-TNI, α- HBDH, CK-MB and... read more
Massive Alveolar Hemorrhage Presenting During the COVID-19 Pandemic
The coronavirus disease (COVID-19) pandemic has challenged healthcare systems and has resulted in complex diagnostic processes for patients with non-COVID-19 pathology. Here, we demonstrate a case of massive alveolar... read more
90 Day Outcomes of COVID-19 Patients in European ICUs
This communication delineates outcomes in COVID-19 patients in the context of ARDS severity, ventilatory management, and variables associated with mortality on a 90-day follow-up for subgroups of patients after ICU admission.... read more
COVID-19: Critical Care and Airway Management Issues
Among patients hospitalized with coronavirus disease 2019 (COVID-19), up to one-quarter require intensive care unit (ICU) admission. Profound hypoxemic respiratory failure from acute respiratory distress syndrome (ARDS)... read more
Prone Position in Intubated, Mechanically Ventilated COVID-19 Patients
During the COVID-19 pandemic, prone position has been widely adopted to treat mechanically ventilated patients with respiratory failure. The majority of patients improved their oxygenation during prone position, most likely... read more
Effects of Ventilatory Rescue Therapies on the Cerebral Oxygenation of COVID-19 Patients
A new study by Masimo published in Critical Care evaluated the impact of a variety of rescue therapies on the systemic and cerebral oxygenation of mechanically ventilated COVID-19 patients suffering from acute respiratory... read more
NeuroRx Announced Completion of Data Analysis for COVID-19 Treatment Respiratory Failure
NeuroRx, Inc. announced completion of top line data analysis of the 60-day results in its phase 2b/3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI™ (aviptadil acetate) for the treatment of critically-ill... read more
Cerecor Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS
Final analysis inclusive of the 60-day safety update in the randomized placebo-controlled study demonstrated CERC-002 was statistically significant in reducing respiratory failure and mortality at Day 28 in patients hospitalized... read more
